Jones Preclinical and Translational Consulting Limited 16442389 false 2025-05-11 2026-05-31 2026-05-31 The principal activity of the company is consultancy services. Digita Accounts Production Advanced 6.30.9574.0 true 16442389 2025-05-11 2026-05-31 16442389 2026-05-31 16442389 core:CurrentFinancialInstruments core:WithinOneYear 2026-05-31 16442389 bus:Micro-entities 2025-05-11 2026-05-31 16442389 bus:AuditExemptWithAccountantsReport 2025-05-11 2026-05-31 16442389 bus:FilletedAccounts 2025-05-11 2026-05-31 16442389 bus:SmallCompaniesRegimeForAccounts 2025-05-11 2026-05-31 16442389 bus:RegisteredOffice 2025-05-11 2026-05-31 16442389 bus:Director1 2025-05-11 2026-05-31 16442389 bus:PrivateLimitedCompanyLtd 2025-05-11 2026-05-31 16442389 bus:Agent1 2025-05-11 2026-05-31 16442389 countries:England 2025-05-11 2026-05-31 iso4217:GBP xbrli:pure

Registration number: 16442389

Jones Preclinical and Translational Consulting Limited

Unaudited Filleted Financial Statements

for the Period from 11 May 2025 to 31 May 2026

 

Jones Preclinical and Translational Consulting Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

2

 

Jones Preclinical and Translational Consulting Limited

Company Information

Director

Mr D G Jones

Registered office

7 Laureate Paddocks
Newmarket
Suffolk
England
CB8 0AP

Accountants

NWG Accountants Limited 86-90 Paul Street
London
London
EC2A 4NE

 

Jones Preclinical and Translational Consulting Limited

(Registration number: 16442389)
Balance Sheet as at 31 May 2026

2026
£

Current assets

74,092

Creditors: Amounts falling due within one year

(27,728)

 

46,364

Capital and reserves

46,364

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
7 Laureate Paddocks
Newmarket
Suffolk
CB8 0AP
England

These financial statements were authorised for issue by the director on 13 July 2026.

2

Staff numbers

The average number of persons employed by the company (including the director) during the period, was 1.

For the financial period ending 31 May 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the micro entities regime and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 13 July 2026
 

.........................................
Mr D G Jones
Director